Alnylam Pharmace. buy StockNews.com
Start price
13.04.24
/
50%
€140.85
Target price
13.04.25
-
Performance (%)
-4.86%
Price
15:32
€134.00
Summary
This prediction is currently active. With a performance of -4.86%, the BUY prediction by StockNews_com is trending in the wrong direction. This prediction currently runs until 13.04.25. The prediction end date can be changed by StockNews_com at any time. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | -1.217% |
| iShares Core DAX® | 2.594% |
| iShares Nasdaq 100 | 3.553% |
| iShares Nikkei 225® | 0.687% |
| iShares S&P 500 | 2.209% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat